An observational study in Gastro -Oesophagal Reflux and Laryngo-pharyngeal Reflux, sponsored by Cleveland Clinic London. Enrolling by invitation at 7 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Cleveland Clinic London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Gastroesophageal Reflux with a site in Austria — 2 open to participants now, 3 under way, none of them phase 3. Gastroesophageal Reflux · Austria.
Among the 26 studies in Gastroesophageal Reflux with a site in Austria, this one is the only one that started in 2023, is one of 8 observational ones, and was the 26th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →2 of the 26 studies in Gastroesophageal Reflux with a site in Austria are open now. Recruiting first, the newest first:
Implantica CE Reflux Ltd. · Sites in Austria, Germany, Switzerland
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 180 across 349 observational studies indexed under Gastroesophageal Reflux.
Median enrollment 160 across the 14 interventional studies, 550 across the 8 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 26 have an industry lead sponsor. The 10 most frequent:
Cleveland Clinic London is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Cleveland Clinic London has 1 study filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastroesophageal Reflux with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07004400Implantica CE Reflux Ltd.A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Gastroesophageal Reflux with a site in Austria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a European, multi-centre, prospective registry that aims to determine the safety and efficacy of transoral incisionless fundoplication, with or without concomitant hiatal hernia repair, for the treatment of patients with gastro-oesophageal reflux disease (GORD).
Patients with gastro-oesophageal reflux disease or laryngo-pharyngeal reflux undergoing transoral incisionless fundoplication with or without concomitant hiatal hernia repair
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Transoral incisionless fundoplication with or without concomitant hiatal hernia repair with the EsophyX device
Transoral Incisionless Fundoplication (TIF): The TIF procedure is an endoscopic, minimally invasive intervention designed to reconstruct the gastro-oesophageal valve and restore its function as a reflux barrier, without external incisions. The procedure is performed transorally using the EsophyX device under general anaesthesia. The device enables the creation of a 270° to 300° esophagogastric fundoplication. Concomitant TIF (cTIF): The cTIF procedure combines a laparoscopic hiatal hernia repair with the TIF performed in the same session. Patients with a hiatal hernia greater than 2 cm undergo laparoscopic reduction and crural repair, followed immediately by the TIF procedure using the EsophyX device. This combined approach addresses both the anatomical defect of the hiatal hernia and the functional deficiency of the gastro-oesophageal valve.
Also known as: TIF, cTIF
Gastroesophageal reflux disease health-related quality of life questionnaire (GERD-HRQL)
Change in reflux-specific quality of life questionnaires (The GERD-HRQL used in the study is composed of 16 questions related to symptoms of heartburn, regurgitation, swallowing and overall satisfaction. Each question provides a scaled score between 0-5 (0=no symptoms, 5= Symptoms incapacitating to do daily activities) with a total score of 75.)
Time frame: 6-months, 1-year, 2-year, 3-years, 5-, years
Reflux symptom index (RSI)
Change in reflux-specific quality of life questionnaire (The RSI used in the study is composed of 9 questions related to atypical symptoms of reflux or 'LPR'. Each question provides a scaled score between 0-5 (0=no problems, 5=severe problems) with a total score of 45.)
Time frame: 6-months, 1-year, 2-years, 3-years, 5-years
Proton pump inhibitor and/or histamine-2 receptor antagonist use
Change in acid suppression use
Time frame: 6-months, 1-year, 2-years, 3-years, 5-years
Physiological reflux testing
Change in pH physiological testing
Time frame: up to 5-years
Procedural outcomes (technical success)
Defined as successful completion of all steps of the cTIF or TIF2.0 procedure in the same sitting
Time frame: 30-days
Procedural outcomes (duration)
Total length of the procedure in minutes
Time frame: 30-days
Procedural outcomes (length of hospital stay
The time in days from procedure to discharge from hospital
Time frame: 30-days
Adverse events
Adverse events (AE) following TIF2.0 according to the AGREE classification
Time frame: up to 30-days
Adverse events of special interest
Subjective reporting of dysphagia, excessive belching or inability to belch, significant bloating and/or distension, and persistent nausea and vomiting.
Time frame: Up to 5-years
Need for revisional procedure
The need for repreat endoscopic or surgical intervention due to recurrence of symptoms, failure of procedure of adverse events
Time frame: Up to 5-years
Plan to share: No — Individual participant data (IPD) will not be shared publicly. Data will be available only to investigators at participating study centers for the purpose of study coordination, monitoring, and analysis in accordance with the study protocol and applicable data protection regulations. Broader sharing of IPD is not planned due to confidentiality considerations and data use agreements established with participating institutions.
Started Jan 2023 (actual). Primary completion is estimated for Jan 2030, 84 months after the start.
Of 95 non-industry observational studies under Gastroesophageal Reflux, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 167. This study's planned 84 months is above that.
Counting every sponsor, half of 117 studies reached it within 45 months; a quarter within 17 and three quarters within 134.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cleveland Clinic London